World's Best Scientists 2026 revealed!
Thomas Bieber

Thomas Bieber

D-Index & Metrics

Immunology

D-Index
107
Citations
41308
World Ranking
548
National Ranking
30

Medicine

D-Index
107
Citations
41451
World Ranking
6265
National Ranking
357

Overview

Thomas Bieber is affiliated with the University of Bonn in Germany and has a research focus primarily within the field of Medicine. Their work spans several important subfields including Dermatology, Immunology and Allergy, Rheumatology, Physiology, and Immunology. The research topics covered by Thomas Bieber include Dermatology and Skin Diseases, Allergic Rhinitis and Sensitization, Asthma and Respiratory Diseases, Food Allergy and Anaphylaxis Research, Urticaria and Related Conditions, Psoriasis: Treatment and Pathogenesis, and Autoimmune Bullous Skin Diseases.

The scientist has contributed extensively to the academic literature, with a significant presence in several publication venues. Frequent journals for their publications include the Journal of the European Academy of Dermatology and Venereology, JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal of the American Academy of Dermatology, British Journal of Dermatology, and Allergy.

Thomas Bieber has collaborated with a range of frequent coauthors, such as Jonathan I. Silverberg, Joerg Wenzel, Andreas Wollenberg, Jacob P. Thyssen, and Eric L. Simpson. These collaborations have supported a robust and diverse research output.

Their recent notable papers include:

  • Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2021) in Nature Reviews Drug Discovery
  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis (2021) in New England Journal of Medicine

Other important recent publications where Thomas Bieber is cited or involved in the domain include:

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial (2020) in The Lancet
  • Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial (2021) in The Lancet
  • Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials (2020) in British Journal of Dermatology

Thomas Bieber's scholarly contributions focus extensively on atopic dermatitis and related inflammatory skin diseases, addressing therapeutic strategies and clinical trial results. Their research has attracted substantial citations, reflecting attention within the dermatology and allergy research communities.

Best Publications

  • Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

    S.G.O Johansson;Thomas Bieber;Ronald Dahl;Peter S Friedmann

  • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

    Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  • Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.

    A Wollenberg;S Barbarot;T Bieber;S Christen-Zaech

  • Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

    C A Akdis;M Akdis;T Bieber;C Bindslev-Jensen

  • Guidelines for treatment of atopic eczema (atopic dermatitis) part I.

    J. Ring;A. Alomar;T. Bieber;M. Deleuran

  • A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

    Thomas Ruzicka;Thomas Bieber;Erwin Schöpf;Andris Rubins

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Cellular and molecular immunologic mechanisms in patients with atopic dermatitis

    Thomas Werfel;Jean-Pierre Allam;Tilo Biedermann;Kilian Eyerich

  • Immune mechanisms leading to atopic dermatitis.

    Natalija Novak;Thomas Bieber;Donald Y.M Leung

  • Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.

    Thomas Bieber

  • Homozygous human TAP peptide transporter mutation in HLA class I deficiency

    Daniel Hanau;Dominique Fricker;Arlette Urlacher

  • Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

    Eric L Simpson;Rodney Sinclair;Seth Forman;Andreas Wollenberg

  • Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

    Marcus Maurer;Sabine Altrichter;Thomas Bieber;Tilo Biedermann

  • Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

    Thomas Bieber;Eric L. Simpson;Jonathan I. Silverberg;Diamant Thaçi

  • Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

    Eric L. Simpson;J.‐P. Lacour;L. Spelman;R. Galimberti

  • Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

    Eric L. Simpson;Carsten Flohr;Lawrence F. Eichenfield;Thomas Bieber

  • Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients

    Michael J. Reinhardt;Alexius Y. Joe;Ursula Jaeger;Andrea Huber

  • Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis.

    Thomas Bieber

  • Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology

    Antonella Muraro;Robert F. Lemanske;Peter W. Hellings;Cezmi A. Akdis

  • Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kristian Reich;Henrique D Teixeira;Marjolein de Bruin-Weller;Thomas Bieber

  • Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus.

    Stephan Weidinger;Christian Gieger;Elke Rodriguez;Hansjörg Baurecht

  • Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

    Eric L. Simpson;Thomas Bieber;Laurent Eckert;Richard Wu

  • Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment

    A Wollenberg;S Reitamo;F Atzori;M Lahfa

Frequent Co-Authors

Natalija Novak
Natalija Novak University of Bonn
Thomas Tüting
Thomas Tüting Otto-von-Guericke University Magdeburg
Thomas Werfel
Thomas Werfel Hannover Medical School
Andreas Wollenberg
Andreas Wollenberg Ludwig-Maximilians-Universität München
Johannes Ring
Johannes Ring Technical University of Munich
Torsten Zuberbier
Torsten Zuberbier Charité - University Medicine Berlin
Hans F. Merk
Hans F. Merk RWTH Aachen University
Jean Bousquet
Jean Bousquet University of Montpellier
Ludger Klimek
Ludger Klimek Ghent University
Thomas Fuchs
Thomas Fuchs University of Göttingen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open various career pathways. Nursing programs, for example, often offer overlap with immunology through clinical practice and patient care, particularly in specialties like infectious diseases and immunodeficiencies.

If you’re looking for flexibility, consider programs such as the easiest absn programs to get into, which accelerate your Bachelor of Science in Nursing and provide a fast track into clinical roles that interact closely with immunology research and care.

For foundational clinical skills, the easiest lpn programs to get into offer practical training and can serve as stepping stones to advanced nursing and immunology-related careers.

Advanced practice roles are also critical. Programs listed under easiest np programs to get into can lead to a Nurse Practitioner career with opportunities to specialize in immunology-linked conditions.

For those passionate about mental health's biological aspects, top options include the top psychiatric mental health nurse practitioner programs online. These focus on psychiatric care but often incorporate immune system research, providing a unique intersection of mental health and immunology.

Best Scientists Citing Thomas Bieber

Trending Scientists